Smith & Nephew plc

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB0009223206
GBP
12.31
-0.03 (-0.2%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Smith & Nephew plc stock-summary
stock-summary
Smith & Nephew plc
Pharmaceuticals & Biotechnology
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.
Company Coordinates stock-summary
Company Details
Building 5, Croxley Park, Hatters Lane , WATFORD None : WD18 8YE
stock-summary
Tel: 44 20 7401764644 20 79602285
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Roberto Quarta
Non-Executive Independent Chairman of the Board
Mr. Roland Diggelmann
Chief Executive Officer, Executive Director
Ms. Anne-Francoise Nesmes
Chief Financial Officer, Executive Director
Dr. Katarzyna Mazur-Hofsaess
Non-Executive Director
Mr. Rick Medlock
Non-Executive Director
Mr. Bob White
Non-Executive Director
The Rt. Hon. Brnss. Virginia Bottomley
Non-Executive Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
789 Million
(Quarterly Results - Dec 2014)
Net Profit:
101 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 10,467 Million (Large Cap)

stock-summary
P/E

31.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

590.13%

stock-summary
Debt Equity

0.48

stock-summary
Return on Equity

9.45%

stock-summary
Price to Book

2.59